Bristol Myers Squibb announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research programs at the 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California. Key data being presented by Bristol Myers Squibb and its partners at the 2024 ASH Annual Meeting and Exposition include: Cell Therapy: Multiple analyses underscoring durable efficacy and well-established safety of the best-in-class profile of Breyanzi®? (lisocabtagene maraleucel; liso-cel) in large B-cell lymphoma (LBCL), including five-year follow-up overall survival (OS) data from the TRANSCEND NHL-001 trial, new data from the Phase 3 TRANSFORM 2L LBCL study showing deeper and more durable responses with Breyanzi over former standard of care using circulating tumor DNA (ctDNA) as an earlier surrogate of clinical outcome, and compelling real-world data from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry; Longer-term results from TRANSCEND FL and TRANSCEND CLL 004 reinforcing Breyanzi's best-in-class and best-in-disease profile in relapsed or refractory (R/R) follicular lymphoma (FL), and its durable responses, sustained complete remissions and updated safety profile in patients with R/R chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Additional evaluations highlighting efficacy and safety from the Phase 1/2 TRANSCEND CLL 00 4 trial analyzing Breyanzi in combination with ibrutinib in patients with R/R CLL and SLL; New analysis highlighting global manufacturing capability, reliability and timely delivery for Abecma®? (idecabtagene vicleucel; ide-cel) in relapsed or refractories multiple myeloma (RRMM). First OS and progression-free survival results from a Phase 1 study of GPRC5D-directed CAR T cell therapy (BMS-986393/CC-95266) across all dose levels, supporting first-in-class potential in both B-cell maturation antigen (BCMA)-naive and BCMA-exposed patients with RRMM; Cell therapy data highlighting its potential beyond blood cancers, with updated Phase 1 data for CD19 NEX-T CAR T in severe, refractory autoimmune diseases, for the first time including patients with multiple sclerosis Anemia; New COMMANDS trial analyses and real-world evidence on long-term benefit of Reblozyl®?

(luspatercept-aamt) for patients with lower-risk myelodysplastic syndromes (MDS) across subgroups, including patients with ringsideroblasts (RS) and low baseline serum erythropoietin (sEPO). Targeted Protein Degradation: Updated results from Phase 1/2 CC-220-MM-001 trial supporting clinical and pharmacological activity of mezigdomide combined with daratumumab and dexamethasone in transplant-ineligible, newly-diagnosed MM patients, including those with high-risk markers; Results from Phase 1/2 CA057-003 trial evaluating an all-oral combination of mezigdomide and novel agents (EZH2, BET and MEK inhibitors), showing promising efficacy and no new safety signals in patients with RRMM; Multiple data sets highlighting the promising clinical profile of golcadomide across LBCL and FL, including new analyses from Phase 1b DLBCL-001 study showing golcadomide plus R-CHOP has high minimal residual disease (MRD) negativity in high-risk 1LBCL, and longer follow-up from the Phase 1/2 NHL-001 study demonstrating the potential of golcadomide in combination with rituximababababtagene (MRD) study demonstrating the potential of golfssEPO) in combination with rituxIMab (R/2L LBCL, and more follow-up from the Phase 2L LBCL, including those with rituximabtagene®? (MRD) in high-up from the Phase 1L, and longer follow-risk 1L, including those with R-up from the Phase 1 LBCL, with rituximabline LBCL, and longer follow the Phase 1L, including the Phase 3.